Erratum: Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer (New England Journal of Medicine (2017) 377 (513-522) DOI: 10.1056/NEJMoa1701717);Analysis of plasma Epstein–Barr virus DNA to screen for nasopharyngeal cancer

New England Journal of Medicine

Volumn 377, Issue 6, 2017, Pages 513-522

  Chan, K C Allen ^a,b,c   Woo, John K S ^b   King, Ann ^b   Zee, Benny C Y ^d   Lam, W K Jacky ^a,b,c   Chan, Stephen L ^c,e   Chu, Sam W I ^a,b,c   Mak, Constance ^a,b,c   Tse, Irene O L ^a,b,c   Leung, Samantha Y M ^a,b,c   Chan, Gloria ^a,b,c   Hui, Edwin P ^c,e   Ma, Brigette B Y ^c,e   Chiu, Rossa W K ^a,b,c   Leung, Sing Fai ^b   Van Hasselt, Andrew C ^b   Chan, Anthony T C ^c,e   Lo, Y M Dennis ^a,b,c  

^a Li Ka Shing Institute of Health Sciences   (Hong Kong)

^b Department of Chemical Pathology ^*

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; ADVANCED CANCER; ARTICLE; ASYMPTOMATIC DISEASE; CANCER SCREENING; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DIAGNOSTIC TEST ACCURACY STUDY; DNA FRAGMENTATION; DNA SCREENING; ENDOSCOPIC BIOPSY; EPSTEIN BARR VIRUS; FEMALE; HAZARD RATIO; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NASAL BIOPSY; NASOPHARYNX CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT DROPOUT; PLASMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SOUTHEAST ASIAN; AGE DISTRIBUTION; BLOOD; CARCINOMA; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; EARLY CANCER DIAGNOSIS; ENDEMIC DISEASE; EPSTEIN-BARR VIRUS INFECTIONS; GENETICS; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; NASOPHARYNGEAL NEOPLASMS; PROCEDURES; VIROLOGY; VIRUS LOAD;

ADULT; AGE DISTRIBUTION; CARCINOMA; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA, VIRAL; EARLY DETECTION OF CANCER; ENDEMIC DISEASES; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 85027045679     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMx180004     Document Type: Erratum

References (36)

1. Cai X, Janku F, Zhan Q, Fan JB. Accessing genetic information with liquid biopsies. Trends Genet 2015;31:564-75.
2. Chan KC, Jiang P, Zheng YW, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 2013;59:211-24.
3. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
4. Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016;8:346ra92.
5. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199-209.
6. Chan KC, Jiang P, Chan CW, et al. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisul-fite sequencing. Proc Natl Acad Sci U S A 2013;110:18761-8.
7. Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012; 4:162ra154.
8. Wong IH, Lo YM, Zhang J, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 1999;59:71-3.
9. Begum S, Brait M, Dasgupta S, et al. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res 2011;17:4494-503.
10. Chan AT, Lo YM, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002;94:1614-9.
11. Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 2015;125:3679-87.
12. Tan DS, Yom SS, Tsao MS, et al. The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: status in 2016. J Thorac Oncol 2016;11:946-63.
13. Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med 2017;376:629-40.
14. Tang LL, Chen WQ, Xue WQ, et al. Global trends in incidence and mortality of nasopharyngeal carcinoma. Cancer Lett 2016;374:22-30.
15. Li K, Lin GZ, Shen JC, Zhou Q. Time trends of nasopharyngeal carcinoma in urban Guangzhou over a 12-year period (2000-2011): declines in both incidence and mortality. Asian Pac J Cancer Prev 2014;15:9899-903.
16. Xie SH, Yu IT, Tse LA, Au JS, Lau JS. Tobacco smoking, family history, and the risk of nasopharyngeal carcinoma: a case-referent study in Hong Kong Chinese. Cancer Causes Control 2015;26:913-21.
17. Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59:1188-91.
18. Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006;24:5414-8.
19. Chan KC, Zhang J, Chan AT, et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 2003;63:2028-32.
20. Lee AW, Sze WM, Au JS, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2005;61:1107-16.
21. Li J, Zou X, Wu YL, et al. A comparison between the sixth and seventh editions of the UICC/AJCC staging system for nasopharyngeal carcinoma in a Chinese cohort. PLoS One 2014;9(12):e116261.
22. Hong Kong Cancer Registry. Nasopharyngeal cancer in 2013 (http://www3.ha.org.hk/cancereg/pdf/factsheet/2013/npc_2013.pdf).
23. Coghill AE, Hsu WL, Pfeiffer RM, et al. Epstein-Barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan. Cancer Epidemiol Biomarkers Prev 2014;23:1213-9.
24. Ng WT, Yau TK, Yung RW, et al. Screening for family members of patients with nasopharyngeal carcinoma. Int J Cancer 2005;113:998-1001.
25. Chan KC, Hung EC, Woo JK, et al. Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. Cancer 2013;119:1838-44.
26. Wong LP, Lai KT, Tsui E, Kwong KH, Tsang RH, Ma ES. Plasma Epstein-Barr virus (EBV) DNA: role as a screening test for nasopharyngeal carcinoma (NPC)? Int J Cancer 2005;117:515-6.
27. Le QT, Zhang Q, Cao H, et al. An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res 2013;19:2208-15.
28. King AD, Vlantis AC, Bhatia KS, et al. Primary nasopharyngeal carcinoma: diagnostic accuracy of MR imaging versus that of endoscopy and endoscopic biopsy. Radiology 2011;258:531-7.
29. AJCC cancer staging manual. 7th ed. New York: Springer, 2010.
30. Chun S, Rhie SY, Ki CS, Kim JE, Park HD. Evaluation of alpha-fetoprotein as a screening marker for hepatocellular carcinoma in hepatitis prevalent areas. Ann Hepatol 2015;14:882-8.
31. Wang HY, Hsieh CH, Wen CN, Wen YH, Chen CH, Lu JJ. Cancers screening in an asymptomatic population by using multiple tumour markers. PLoS One 2016; 11(6):e0158285.
32. Zhang MX, Li J, Shen GP, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. Eur J Cancer 2015;51:2587-95.
33. Lo SS, Lu JJ. Natural history, presenting symptoms, and diagnosis of nasopharyngeal carcinoma. In: Lu JJ, Cooper JS, Lee AWM, eds. Nasopharyngeal cancer: multidisciplinary management. Berlin: Springer-Verlag, 2010:41-52.
34. Pak MW, To KF, Lo YM, et al. Nasopharyngeal carcinoma in situ (NPCIS) — pathologic and clinical perspectives. Head Neck 2002;24:989-95.
35. To EW, Chan KC, Leung SF, et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res 2003; 9:3254-9.
36. Andersson-Anvret M, Forsby N, Klein G, Henle W. Relationship between the Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: correlated nucleic acid hybridization and histopathological examination. Int J Cancer 1977;20:486-94.